Matches in Wikidata for { <http://www.wikidata.org/entity/Q66071889> ?p ?o ?g. }
Showing items 1 to 33 of
33
with 100 items per page.
- Q66071889 description "clinical trial" @default.
- Q66071889 description "ensayu clínicu" @default.
- Q66071889 description "klinisch onderzoek" @default.
- Q66071889 description "клінічне випробування" @default.
- Q66071889 name "Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan" @default.
- Q66071889 name "Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan" @default.
- Q66071889 type Item @default.
- Q66071889 label "Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan" @default.
- Q66071889 label "Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan" @default.
- Q66071889 prefLabel "Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan" @default.
- Q66071889 prefLabel "Mirabegron Treatment on Patients With Overactive Bladder Syndrome in Taiwan" @default.
- Q66071889 P1050 Q66071889-2534738F-29B3-4746-8C39-8CC097F8EE70 @default.
- Q66071889 P1050 Q66071889-CB7189EB-A42C-4717-9515-38CAE97D4B66 @default.
- Q66071889 P1132 Q66071889-1F2DA146-FAD9-430D-89AE-19CFED485573 @default.
- Q66071889 P1476 Q66071889-8425D527-F4D5-4406-85ED-C79665EA3145 @default.
- Q66071889 P2899 Q66071889-E8BE7104-28EC-47A3-A4DB-EC3E460B3B54 @default.
- Q66071889 P3098 Q66071889-43FFC178-CEAD-4886-84D7-F3ABB6D4EC1D @default.
- Q66071889 P31 Q66071889-6D90AD1C-9834-4DE5-BAFF-FF8C8E662A36 @default.
- Q66071889 P580 Q66071889-0E48394F-CC15-4EBF-B5C9-266513767E6A @default.
- Q66071889 P582 Q66071889-5024D274-CBB7-441C-931B-18471A86B72B @default.
- Q66071889 P6099 Q66071889-C444ED22-A6D9-4D12-8F7F-9F8FDCFA70D2 @default.
- Q66071889 P8363 Q66071889-20E56DA8-49C8-4E3E-8F70-1BBEF66BD7B4 @default.
- Q66071889 P1050 Q179630 @default.
- Q66071889 P1050 Q281490 @default.
- Q66071889 P1132 "+168" @default.
- Q66071889 P1476 "Therapeutic Efficacy and Safety of Mirabegron , a β3-Adrenoceptor Agonist, Treatment on Patients With Overactive Bladder Syndrome in Taiwan - Predictive Factors for the First Line Use and the Dose Effectiveness Relationship" @default.
- Q66071889 P2899 "+18" @default.
- Q66071889 P3098 "NCT03059134" @default.
- Q66071889 P31 Q30612 @default.
- Q66071889 P580 "2015-04-28T00:00:00Z" @default.
- Q66071889 P582 "2016-04-27T00:00:00Z" @default.
- Q66071889 P6099 Q42824827 @default.
- Q66071889 P8363 Q78089383 @default.